Draelos, Zoe D.
297  Ergebnisse:
Personensuche X
?
2

53797 Fixed-Combination Halobetasol Propionate 0.01% and Ta..:

Lebwohl, Mark ; Han, George ; Draelos, Zoe..
Journal of the American Academy of Dermatology.  91 (2024)  3 - p. AB46 , 2024
 
?
3

504 - Investigator- and patient-rated local tolerability in..:

Bunick, Christopher G ; Bhatia, Neal ; Del Rosso, James...
British Journal of Dermatology.  190 (2024)  Supplement_2 - p. ii9-ii10 , 2024
 
?
4

Clinical Evaluation of Next-Generation, Multi-Weight Hyalur..:

Romanowitz, Daniel ; Lain, Edward ; Mariwalla, Kavita...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s346 , 2024
 
?
5

53978 Effectiveness and Safety of a Resilient Hyaluronic Ac..:

Shamban, Ava ; Fabi, Sabrina ; Dayan, Steven H....
Journal of the American Academy of Dermatology.  91 (2024)  3 - p. AB192 , 2024
 
?
6

Impact of Age on Efficacy and Safety of Fixed-Dose Clindamy..:

Kircik, Leon H. ; Harper, Julie C. ; Baldwin, Hilary...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  4 - p. s415 , 2024
 
?
 
?
 
?
 
?
10

52858 Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15..:

Kircik, Leon ; Draelos, Zoe ; Gold, Michael..
Journal of the American Academy of Dermatology.  91 (2024)  3 - p. AB198 , 2024
 
?
11

Evaluation of Antioxidants' Ability to Enhance Hyaluronic A..:

Romanowitz, Daniel ; Zeichner, Joshua ; Lain, Edward...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s348 , 2024
 
?
12

Investigator- and Patient-Rated Local Tolerability in Phase..:

Bunick, Christopher ; Bhatia, Neal ; Del Rosso, James...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s309 , 2024
 
?
13

Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzo..:

Kircik, Leon ; Draelos, Zoe D. ; Gold, Michael..
SKIN The Journal of Cutaneous Medicine.  8 (2024)  4 - p. s416 , 2024
 
?
 
?
15

Roflumilast foam 0.3% for adolescent and adult patients wit..:

Blauvelt, Andrew ; Draelos, Zoe D. ; Stein Gold, Linda...
Journal of the American Academy of Dermatology.  90 (2024)  5 - p. 986-993 , 2024
 
1-15